Original Article
Copyright ©2014 Baishideng Publishing Group Co.
World J Gastrointest Endosc. Jan 16, 2014; 6(1): 13-19
Published online Jan 16, 2014. doi: 10.4253/wjge.v6.i1.13
Table 1 Overview of all patients treated with radiofrequency ablation for hilar malignancies included in our study
PatientPatient gender/ageTumor locationNo. of RFA treatment cyclesFollow-up (mo)Outcome
1F/78CCA Bismuth IV26.4Dead
2F/73Intrahepatic CCA10.3Dead
3M/72CCA Bismuth IV519.8Alive
4M/85CCA Bismuth IV26.2Dead
5M/81CCA Bismuth IV11.1Dead
6M/33Gastric carcinoma1Lost to follow up-
7F/77Gallbladder cancer16.6Dead
8F/78CCA Bismuth IV11.3Dead
9M/47CCA Bismuth IV114.1Alive
10F/78CCA Bismuth IV11.2Dead
11M/61Gallbladder cancer14.0Alive
12M/72Intrahepatic CCA12.9Alive
Table 2 Literature overview of studies investigating the use of endoscopically-guided intraductal radiofrequency ablation in malignant biliary obstruction, localization of included tumors and complications are also listed for each study
Ref.YearnLocalization of the tumorComplications
Figueroa-Barojas et al[15]20118Intra- and extra-hepaticPain: 4
Pancreatitis and Cholecystitis: 1
Steel et al[12]201121ExtrahepaticEmpyema of the gallbladder: 1
Dolak et al[16]201243IntrahepaticHemobilia: 2
Liver infarction: 1
Empyema of the gallbladder: 1
Cholangitis: 1
Mizandari et al[17]201239Intra- and extrahepaticPain: 15
Own experience201312IntrahepaticHemobilia: 3 (2 deaths)